^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)

    i
    Other names: RG7446 SC, RO5541267 SC, MPDL-3280A SC, atezolizumab/rHuPH20, RG7446/rHuPH20, MPDL3280A SC, RG-7446 SC, RO-5541267 SC, MPDL 3280A SC, RG 7446 SC, RO 5541267 SC
    Company:
    Halozyme, Roche
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    9d
    Exploratory Analyses of Patient Preferences for Atezolizumab Subcutaneous Versus Intravenous from the IMscin002 Study in Patients with Non-Small Cell Lung Cancer. (PubMed, Oncol Ther)
    Most patients preferred atezolizumab SC regardless of baseline characteristics, mean injection duration, and cumulative number of SC injections. The trend for a stronger preference was higher among patients who preferred SC than those who preferred IV. Our findings suggest that the proportion of preference for atezolizumab SC over IV is highest in patients aged > 74 years, and that administrator's experience could be an important factor influencing patient preference.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    EGFR wild-type • ALK wild-type
    |
    Tecentriq (atezolizumab) • Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
    4ms
    Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=5, Terminated, University of Southern California | N=37 --> 5 | Trial completion date: Dec 2026 --> Jul 2025 | Recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Jul 2025; insufficient accrual
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
    8ms
    Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC. (PubMed, JTO Clin Res Rep)
    There were no new safety findings, and switching between the administration routes was well tolerated. These results support the preference for SC formulations to reduce the treatment burden.
    Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
    11ms
    IMscin001: A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=438, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion
    |
    EGFR (Epidermal growth factor receptor)
    |
    Tecentriq (atezolizumab) • Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
    1year
    IMscin002: A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=179, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
    over1year
    ORIGAMA: Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice (clinicaltrials.gov)
    P2/3, N=49, Terminated, Hoffmann-La Roche | N=440 --> 49 | Trial completion date: Jul 2026 --> Jul 2024 | Active, not recruiting --> Terminated; Study terminated by sponsor.
    Enrollment change • Trial completion date • Trial termination • HEOR
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
    over1year
    ORIGAMA: Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice (clinicaltrials.gov)
    P2/3, N=440, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
    Enrollment closed • HEOR
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
    over2years
    A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=176, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
    over2years
    A phase II, multicenter, open-label study of PolyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301): Initial results (ESMO 2023)
    Methods Patients with MSS mCRC who have progressed on 2-3 lines of prior chemotherapy regimen received PolyPEPI1018 (1.2 mg, sc) and atezolizumab (1,200 mg, iv) Q3W. PolyPEPI1018 induced immunological responses at both peripheral and tumor level, converted "cold" tumor into "hot", although to date no responses per RECIST have been noted. The study is on-going.
    Combination therapy • P2 data • Clinical • PD(L)-1 Biomarker • MSi-H Biomarker • IO biomarker • Metastases
    |
    MSI (Microsatellite instability) • CD8 (cluster of differentiation 8)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    Immunoscore®
    |
    Tecentriq (atezolizumab) • Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) • PolyPEPI 1018
    over2years
    IMscin001 Part 2: A randomised phase III, open-label, multicentre study examining the pharmacokinetics (PK), efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous in previously treated locally advanced or metastatic non-small-cell lung cancer and PK comparison to other approved indications. (PubMed, Ann Oncol)
    Compared with IV, atezolizumab SC demonstrated noninferior drug exposure at cycle 1. Efficacy, safety, and immunogenicity were similar between arms and consistent with the known profile for atezolizumab IV. Similar drug exposure and clinical outcomes following SC and IV administration support the use of atezolizumab SC as an alternative to atezolizumab IV.
    P3 data • PK/PD data • Journal • Metastases
    |
    Tecentriq (atezolizumab) • Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
    over2years
    ORIGAMA: Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice (clinicaltrials.gov)
    P2/3, N=440, Recruiting, Hoffmann-La Roche | Phase classification: P2 --> P2/3
    Phase classification • HEOR
    |
    PD-L1 (Programmed death ligand 1) • IL6 (Interleukin 6)
    |
    PD-L1 expression
    |
    Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
    over2years
    A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=175, Recruiting, Hoffmann-La Roche | Trial completion date: Mar 2024 --> Jul 2024 | Trial primary completion date: Jul 2023 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)